Aktienanalyse zu Aptevo Therapeutics Inc (APVO)APVOAptevo Therapeutics Inc

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aptevo Therapeutics is not a good buy right now due to its significantly negative financial performance and poor technical indicators. The current price is $2.37, and the RSI is extremely low at 16.495, indicating oversold conditions. Additionally, the company has a forward P/E of 3.8895, which suggests it is undervalued, but the recent 5-day change of -11.75% and 20-day change of -42.46% indicate a strong downward trend. The main risk is the company's continued negative earnings, with a GAAP EPS of -$87.27 reported, which raises concerns about its financial viability.

1 analysts cover APVO: 1 rate it Buy, 0 Hold and 0 Sell.